|
NO2694640T3
(cg-RX-API-DMAC10.html)
|
2011-04-15 |
2018-03-17 |
|
|
|
EP3494974B1
(en)
|
2011-07-08 |
2023-10-18 |
The University of North Carolina at Chapel Hill |
Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
|
|
CA2902174A1
(en)
|
2013-03-14 |
2014-10-02 |
Newlink Genetics Corporation |
Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
|
|
JP6603649B2
(ja)
|
2013-03-14 |
2019-11-06 |
キュラデブ ファーマ プライベート リミテッド |
キヌレニン経路の阻害剤
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
CN103382187B
(zh)
*
|
2013-08-06 |
2015-06-03 |
信实生物医药（上海）有限公司 |
一种3-氯-7(5)-溴苯并异恶唑的合成方法
|
|
EA201990240A1
(ru)
|
2013-12-24 |
2019-06-28 |
Бристол-Маерс Сквибб Компани |
Новые трициклические соединения в качестве противораковых средств
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
PL3151921T3
(pl)
|
2014-06-06 |
2020-02-28 |
Bristol-Myers Squibb Company |
Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania
|
|
AU2015311826B2
(en)
|
2014-09-05 |
2019-05-23 |
Merck Patent Gmbh |
Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (IDO) antagonists for the treatment of cancer
|
|
GB201417369D0
(en)
*
|
2014-10-01 |
2014-11-12 |
Redx Pharma Ltd |
Compounds
|
|
GB201418300D0
(en)
*
|
2014-10-15 |
2014-11-26 |
Redx Pharma Ltd |
Compounds
|
|
NZ731185A
(en)
|
2014-10-29 |
2024-03-22 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for mt1-mmp
|
|
JP6805142B2
(ja)
|
2014-11-21 |
2020-12-23 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
Ｃｄ７３に対する抗体およびその使用
|
|
WO2016100851A1
(en)
|
2014-12-18 |
2016-06-23 |
Lankenau Institute For Medical Research |
Methods and compositions for the treatment of retinopathy and other ocular diseases
|
|
AR103232A1
(es)
|
2014-12-22 |
2017-04-26 |
Bristol Myers Squibb Co |
ANTAGONISTAS DE TGFbR
|
|
AR103268A1
(es)
|
2014-12-23 |
2017-04-26 |
Bristol Myers Squibb Co |
Anticuerpos contra tigit
|
|
WO2016127052A1
(en)
|
2015-02-05 |
2016-08-11 |
Bristol-Myers Squibb Company |
Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy
|
|
CN105884828A
(zh)
*
|
2015-02-16 |
2016-08-24 |
上海迪诺医药科技有限公司 |
多环化合物、其药物组合物及应用
|
|
JP6836998B2
(ja)
|
2015-03-02 |
2021-03-03 |
ライジェル ファーマシューティカルズ， インコーポレイテッド |
ＴＧＦ−β阻害剤
|
|
MX2017012738A
(es)
|
2015-04-03 |
2017-11-15 |
Bristol Myers Squibb Co |
Inhibidores de indolamina 2.3-dioxigenasa (ido) para el tratamiento de cancer.
|
|
WO2016162505A1
(en)
|
2015-04-08 |
2016-10-13 |
F-Star Biotechnology Limited |
Her2 binding agent therapies
|
|
EP3280715B1
(en)
*
|
2015-04-10 |
2020-11-25 |
Beigene, Ltd. |
NOVEL 5 OR 8-SUBSTITUTED IMIDAZO [1, 5-a]PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES
|
|
EP3283488A4
(en)
*
|
2015-04-12 |
2018-10-24 |
Hangzhou Innogate Pharma Co., Ltd. |
Heterocycles useful as ido and tdo inhibitors
|
|
CA2980460A1
(en)
|
2015-04-13 |
2016-10-20 |
Five Prime Therapeutics, Inc. |
Combination therapy for cancer
|
|
CN106715440B
(zh)
*
|
2015-04-21 |
2019-02-22 |
江苏恒瑞医药股份有限公司 |
咪唑并异吲哚类衍生物、其制备方法及其在医药上的应用
|
|
WO2016183114A1
(en)
|
2015-05-11 |
2016-11-17 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
|
US9725449B2
(en)
|
2015-05-12 |
2017-08-08 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
|
WO2016183115A1
(en)
|
2015-05-12 |
2016-11-17 |
Bristol-Myers Squibb Company |
5h-pyrido[3,2-b]indole compounds as anticancer agents
|
|
AU2016271111B2
(en)
|
2015-05-29 |
2022-04-28 |
Bristol-Myers Squibb Company |
Antibodies against OX40 and uses thereof
|
|
GB2548542A
(en)
*
|
2015-06-16 |
2017-09-27 |
Redx Pharma Plc |
Compounds
|
|
CN106256830B
(zh)
*
|
2015-06-18 |
2019-03-08 |
成都海创药业有限公司 |
一种氘代的ido抑制剂及其制备方法和用途
|
|
MX2017016502A
(es)
|
2015-06-29 |
2018-03-12 |
Univ Rockefeller |
Anticuerpos contra cd40 con actividad agonista mejorada.
|
|
CN105037371A
(zh)
*
|
2015-06-30 |
2015-11-11 |
西华大学 |
一种氘代的吲哚胺-2,3-双加氧酶抑制剂
|
|
GB201511790D0
(en)
|
2015-07-06 |
2015-08-19 |
Iomet Pharma Ltd |
Pharmaceutical compound
|
|
MX2017016844A
(es)
|
2015-07-16 |
2018-08-15 |
Biokine Therapeutics Ltd |
Composiciones y procedimientos para tratar cancer.
|
|
PE20180928A1
(es)
|
2015-07-24 |
2018-06-08 |
Newlink Genetics Corp |
Sales y profarmacos de 1-metil-d-triptofano
|
|
US10399987B2
(en)
|
2015-07-28 |
2019-09-03 |
Bristol-Myer Squibb Company |
TGF beta receptor antagonists
|
|
EP3337476A4
(en)
|
2015-08-19 |
2019-09-04 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
CN108349976A
(zh)
|
2015-08-25 |
2018-07-31 |
百时美施贵宝公司 |
TGFβ受体拮抗剂
|
|
CN106478634B
(zh)
*
|
2015-09-01 |
2020-05-22 |
尚华医药科技(江西)有限公司 |
稠合咪唑化合物、其制备方法、药物组合物和用途
|
|
US10308647B2
(en)
|
2015-10-29 |
2019-06-04 |
Scifluor Life Sciences, Inc. |
Fused imidazole derivatives as IDO/TDO inhibitors
|
|
CA3001131A1
(en)
|
2015-11-02 |
2017-05-11 |
Five Prime Therapeutics, Inc. |
Cd80 extracellular domain polypeptides and their use in cancer treatment
|
|
HK1254241A1
(zh)
*
|
2015-11-09 |
2019-07-12 |
F. Hoffmann-La Roche Ag |
用於鉴定ido1和/或tdo调节剂的筛选测定法
|
|
MX2018006072A
(es)
|
2015-11-19 |
2018-08-01 |
Squibb Bristol Myers Co |
Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.
|
|
SG10201913538VA
(en)
|
2015-11-23 |
2020-02-27 |
Five Prime Therapeutics Inc |
Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
|
|
US10450318B2
(en)
|
2015-12-15 |
2019-10-22 |
Bristol-Myers Squibb Company |
CXCR4 receptor antagonists
|
|
CN110072864B
(zh)
*
|
2015-12-24 |
2022-05-27 |
基因泰克公司 |
Tdo2抑制剂
|
|
CN107056785B
(zh)
*
|
2016-01-02 |
2021-06-22 |
杭州英创医药科技有限公司 |
作为ido和tdo抑制剂的杂环化合物
|
|
WO2017134555A1
(en)
|
2016-02-02 |
2017-08-10 |
Emcure Pharmaceuticals Limited |
Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
|
|
EP3416725A1
(en)
|
2016-02-19 |
2018-12-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of obesity
|
|
US10487088B2
(en)
|
2016-02-19 |
2019-11-26 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Tricyclic compound serving as immunomodulator
|
|
WO2017140272A1
(zh)
*
|
2016-02-19 |
2017-08-24 |
正大天晴药业集团股份有限公司 |
作为免疫调节剂的三并环化合物
|
|
WO2017149469A1
(en)
|
2016-03-03 |
2017-09-08 |
Emcure Pharmaceuticals Limited |
Heterocyclic compounds useful as ido and/or tdo modulators
|
|
AU2017228470A1
(en)
|
2016-03-04 |
2018-08-30 |
Bristol-Myers Squibb Company |
Combination therapy with anti-CD73 antibodies
|
|
BR112018071307A2
(pt)
|
2016-04-18 |
2019-02-26 |
Celldex Therapeutics, Inc. |
anticorpos agonistas que ligam cd40 humana e usos dos mesmos
|
|
CN105732643A
(zh)
*
|
2016-04-18 |
2016-07-06 |
苏州大学 |
一种偶联物、其制备方法及在制备ido酶抑制剂和非甾体抗炎药物中的应用
|
|
CN107312005B
(zh)
*
|
2016-04-27 |
2021-12-17 |
上海翰森生物医药科技有限公司 |
具有ido/tdo抑制活性的稠合咪唑衍生物及其制备方法和应用
|
|
WO2017192844A1
(en)
|
2016-05-04 |
2017-11-09 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
US10544099B2
(en)
|
2016-05-04 |
2020-01-28 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
EP3452450A1
(en)
|
2016-05-04 |
2019-03-13 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
EP3452452A4
(en)
|
2016-05-04 |
2019-10-30 |
Bristol-Myers Squibb Company |
INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE AND METHOD FOR THEIR USE
|
|
EP3452451A4
(en)
|
2016-05-04 |
2019-11-13 |
Bristol-Myers Squibb Company |
INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
|
|
WO2017197046A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
C3-carbon linked glutarimide degronimers for target protein degradation
|
|
CN109562113A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的螺环降解决定子体
|
|
CN121974842A
(zh)
|
2016-05-10 |
2026-05-05 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
CN109562107A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的杂环降解决定子体
|
|
CN107383012B
(zh)
*
|
2016-05-16 |
2021-09-28 |
鲁南制药集团股份有限公司 |
含二环的咪唑醇衍生物
|
|
CN107556316B
(zh)
*
|
2016-06-30 |
2021-11-12 |
鲁南制药集团股份有限公司 |
含桥环的咪唑衍生物
|
|
CN105902542A
(zh)
*
|
2016-05-16 |
2016-08-31 |
张阳 |
一种偶联物在制备治疗心血管疾病药物中的应用
|
|
WO2017198159A1
(zh)
*
|
2016-05-16 |
2017-11-23 |
鲁南制药集团股份有限公司 |
含桥环的咪唑衍生物
|
|
CN106957318B
(zh)
*
|
2016-05-19 |
2019-12-10 |
中国科学院上海有机化学研究所 |
稠合多环吲哚啉化合物、其制备方法、药物组合物及应用
|
|
CN109310702A
(zh)
|
2016-05-20 |
2019-02-05 |
芝加哥大学 |
用于化学疗法、靶向疗法、光动力疗法、免疫疗法和它们的任何组合的纳米颗粒
|
|
JOP20170131B1
(ar)
|
2016-06-10 |
2021-08-17 |
Lilly Co Eli |
مركبات 1-تيترا هيدروبيرانييل كاربونيل -2،3-ديهيدرو -1 h- اندول لعلاج السرطان
|
|
CN107488179B
(zh)
*
|
2016-06-11 |
2024-06-07 |
鲁南制药集团股份有限公司 |
含桥环的咪唑醇衍生物
|
|
CN107556315B
(zh)
*
|
2016-06-30 |
2021-08-31 |
鲁南制药集团股份有限公司 |
含四元环的咪唑衍生物
|
|
US20190248893A1
(en)
|
2016-07-14 |
2019-08-15 |
Bristol-Myers Squibb Company |
Antibodies against tim3 and uses thereof
|
|
US20190292179A1
(en)
|
2016-07-21 |
2019-09-26 |
Bristol-Myers Squibb Company |
TGF Beta RECEPTOR ANTAGONISTS
|
|
CN107663159A
(zh)
*
|
2016-07-29 |
2018-02-06 |
上海迪诺医药科技有限公司 |
多环化合物、其药物组合物及应用
|
|
WO2018028491A1
(zh)
*
|
2016-08-09 |
2018-02-15 |
苏州国匡医药科技有限公司 |
吲哚胺2，3-双加氧酶抑制剂及其在药学中的用途
|
|
EP3503916A1
(en)
|
2016-08-26 |
2019-07-03 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
WO2018045966A1
(zh)
*
|
2016-09-12 |
2018-03-15 |
广州必贝特医药技术有限公司 |
含咪唑稠合三环类化合物及其应用
|
|
TW201815766A
(zh)
|
2016-09-22 |
2018-05-01 |
美商普雷辛肯公司 |
用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症
|
|
EP3515914A4
(en)
|
2016-09-24 |
2020-04-15 |
BeiGene, Ltd. |
INNOVATIVE 5- OR 8-SUBSTITUTED IMIDAZO [1,5-A] PYRIDINE AS SELECTIVE INHIBITORS OF INDOLEAMINE AND / OR TRYPTOPHANE-2,3-DIOXYGENASES
|
|
EP3525803B1
(en)
|
2016-10-13 |
2022-12-07 |
Juno Therapeutics, Inc. |
Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
|
|
TW201815793A
(zh)
*
|
2016-10-21 |
2018-05-01 |
江蘇恆瑞醫藥股份有限公司 |
一種咪唑並異吲哚類衍生物的遊離鹼的結晶形式及其製備方法
|
|
WO2018072743A1
(zh)
*
|
2016-10-21 |
2018-04-26 |
苏州盛迪亚生物医药有限公司 |
Pd-1抗体与ido抑制剂联合在制备抗肿瘤的药物中的用途
|
|
EP3535243B1
(en)
|
2016-11-04 |
2021-12-15 |
Auckland Uniservices Limited |
Substituted 9h-xanthen-9-one, 9h-thioxanthen-9-one and acridin-9(10h)-one derivatives and related compounds csf-1r inhibitors for the treatment of cancer
|
|
CN106474468B
(zh)
*
|
2016-11-23 |
2020-03-27 |
中国医学科学院医学生物学研究所 |
一种复合佐剂、含该复合佐剂的疫苗及疫苗的制备方法
|
|
WO2018106579A1
(en)
*
|
2016-12-06 |
2018-06-14 |
Albert Einstein College Of Medicine, Inc. |
Drug targeting of human indoleamine 2,3-dioxygenase
|
|
EP3560928B1
(en)
*
|
2016-12-20 |
2021-10-20 |
Shenzhen Chipscreen Biosciences Co., Ltd. |
Fused imidazole compound having indoleamine 2,3-dioxygenase inhibitory activity
|
|
WO2018119440A1
(en)
|
2016-12-22 |
2018-06-28 |
Calithera Biosciences, Inc. |
Compositions and methods for inhibiting arginase activity
|
|
CN108239091B
(zh)
*
|
2016-12-26 |
2021-08-13 |
中国医学科学院药物研究所 |
1-环己基-2-(5H-咪唑[5,1-a]异吲哚)乙基-1-酮的拆分
|
|
US10961239B2
(en)
|
2017-01-05 |
2021-03-30 |
Bristol-Myers Squibb Company |
TGF beta receptor antagonists
|
|
WO2018136437A2
(en)
|
2017-01-17 |
2018-07-26 |
Tesaro, Inc. |
Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
|
|
WO2018175954A1
(en)
|
2017-03-23 |
2018-09-27 |
F. Hoffmann-La Roche Ag |
Synthesis of imidazo[5,1-a]isoindole derivative useful as ido inhibitors
|
|
EP3601353A1
(en)
|
2017-03-31 |
2020-02-05 |
Five Prime Therapeutics, Inc. |
Combination therapy for cancer using anti-gitr antibodies
|
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
|
MX2019012431A
(es)
|
2017-04-21 |
2020-08-03 |
Ikena Oncology Inc |
Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
|
|
CN110546509A
(zh)
|
2017-04-28 |
2019-12-06 |
戊瑞治疗有限公司 |
用cd80细胞外结构域多肽进行治疗的方法
|
|
WO2018209049A1
(en)
|
2017-05-12 |
2018-11-15 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
CN107176956B
(zh)
*
|
2017-05-31 |
2019-11-12 |
成都海博锐药业有限公司 |
一种ido抑制剂化合物、药用组合物、用途
|
|
EP4717317A3
(en)
|
2017-06-20 |
2026-06-03 |
C4 Therapeutics, Inc. |
N/o-linked degrons and degronimers for protein degradation
|
|
WO2019002842A1
(en)
|
2017-06-26 |
2019-01-03 |
Bicyclerd Limited |
BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF
|
|
EP3645533B1
(en)
|
2017-06-28 |
2025-03-26 |
Genentech, Inc. |
Tdo2 and ido1 inhibitors
|
|
US11827639B2
(en)
|
2017-06-28 |
2023-11-28 |
Genentech, Inc. |
TDO2 and IDO1 inhibitors
|
|
KR102630575B1
(ko)
|
2017-06-30 |
2024-01-29 |
브리스톨-마이어스 스큅 컴퍼니 |
Ido 억제제의 무정형 및 결정질 형태
|
|
WO2019023459A1
(en)
|
2017-07-28 |
2019-01-31 |
Bristol-Myers Squibb Company |
CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
|
|
WO2019028250A1
(en)
|
2017-08-02 |
2019-02-07 |
The University Of Chicago |
NOMOGENEOUS ORGANOMETALLIC ORGANOMETRIC ORGANOMETRIC LAYERS FOR X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RODIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF
|
|
JP7670481B2
(ja)
|
2017-08-04 |
2025-04-30 |
バイスクルテクス・リミテッド |
Ｃｄ１３７に対して特異的な二環式ペプチドリガンド
|
|
TW201910336A
(zh)
*
|
2017-08-08 |
2019-03-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
一種咪唑并異吲哚類衍生物的製備方法
|
|
CN109384791B
(zh)
*
|
2017-08-09 |
2020-09-11 |
江苏恒瑞医药股份有限公司 |
一种咪唑并异吲哚类衍生物游离碱的晶型及其制备方法
|
|
CN111163766A
(zh)
|
2017-08-17 |
2020-05-15 |
医肯纳肿瘤学公司 |
Ahr抑制剂和其用途
|
|
TW201920202A
(zh)
|
2017-08-17 |
2019-06-01 |
瑞士商愛杜西亞製藥有限公司 |
吲哚胺2,3-二氧酶及/或色胺酸2,3-二氧酶的抑制劑
|
|
US11236107B2
(en)
|
2017-08-18 |
2022-02-01 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Crystal of tricyclic compound
|
|
KR102891807B1
(ko)
*
|
2017-08-22 |
2025-12-01 |
길리애드 사이언시즈, 인코포레이티드 |
치료 헤테로시클릭 화합물
|
|
JP7208225B2
(ja)
|
2017-08-31 |
2023-01-18 |
ブリストル－マイヤーズ スクイブ カンパニー |
抗癌剤としての環状ジヌクレオチド
|
|
EP3676277A1
(en)
|
2017-08-31 |
2020-07-08 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
US10947263B2
(en)
|
2017-08-31 |
2021-03-16 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
CN107501272B
(zh)
*
|
2017-09-05 |
2020-03-31 |
中国药科大学 |
咪唑并异吲哚类ido1抑制剂、其制备方法及应用
|
|
EP4176876A1
(en)
|
2017-09-14 |
2023-05-10 |
Lankenau Institute for Medical Research |
Methods and compositions for the treatment of cancer
|
|
MX2020003190A
(es)
|
2017-09-22 |
2020-11-11 |
Kymera Therapeutics Inc |
Degradadores de proteinas y usos de los mismos.
|
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
|
WO2019074822A1
(en)
|
2017-10-09 |
2019-04-18 |
Bristol-Myers Squibb Company |
INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
|
|
US11203592B2
(en)
|
2017-10-09 |
2021-12-21 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
US11660311B2
(en)
|
2017-10-10 |
2023-05-30 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
WO2019075090A1
(en)
|
2017-10-10 |
2019-04-18 |
Tilos Therapeutics, Inc. |
ANTI-LAP ANTIBODIES AND USES THEREOF
|
|
ES2997757T3
(en)
|
2017-10-16 |
2025-02-18 |
Bristol Myers Squibb Co |
Cyclic dinucleotides as anticancer agents
|
|
JP7306634B2
(ja)
|
2017-10-19 |
2023-07-11 |
一般社団法人ファルマバレープロジェクト支援機構 |
Ｉｄｏ／ｔｄｏ阻害剤
|
|
US11603410B2
(en)
|
2017-11-01 |
2023-03-14 |
Bristol-Myers Squibb Company |
Immunostimulatory agonistic antibodies for use in treating cancer
|
|
WO2019090198A1
(en)
|
2017-11-06 |
2019-05-09 |
Bristol-Myers Squibb Company |
Isofuranone compounds useful as hpk1 inhibitors
|
|
US11472788B2
(en)
|
2017-11-25 |
2022-10-18 |
Beigene, Ltd. |
Benzoimidazoles as selective inhibitors of indoleamine 2,3-dioxygenases
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
CN111788227B
(zh)
|
2017-12-27 |
2025-02-25 |
百时美施贵宝公司 |
抗cd40抗体及其用途
|
|
US11447449B2
(en)
|
2018-01-05 |
2022-09-20 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
EP3737666A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
|
|
US11512080B2
(en)
|
2018-01-12 |
2022-11-29 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
|
JP7358361B2
(ja)
|
2018-01-12 |
2023-10-10 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｔｉｍ３に対する抗体およびその使用
|
|
ES2907282T3
(es)
|
2018-01-15 |
2022-04-22 |
Idorsia Pharmaceuticals Ltd |
Inhibidores de la indoleamina 2,3-dioxigenasa y/o de la triptófano dioxigenasa
|
|
WO2019141095A1
(zh)
*
|
2018-01-19 |
2019-07-25 |
四川科伦博泰生物医药股份有限公司 |
脒类和胍类衍生物、其制备方法及其在医药上的应用
|
|
CA3089762A1
(en)
|
2018-01-29 |
2019-08-01 |
Merck Patent Gmbh |
Gcn2 inhibitors and uses thereof
|
|
AU2019212969B2
(en)
|
2018-01-29 |
2025-01-23 |
Merck Patent Gmbh |
GCN2 inhibitors and uses thereof
|
|
US10519187B2
(en)
|
2018-02-13 |
2019-12-31 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
CA3091775A1
(en)
|
2018-02-23 |
2019-08-29 |
Bicycletx Limited |
Multimeric bicyclic peptide ligands
|
|
JP7250808B2
(ja)
|
2018-03-08 |
2023-04-03 |
ブリストル－マイヤーズ スクイブ カンパニー |
抗がん剤としての環状ジヌクレオチド
|
|
US11149011B2
(en)
|
2018-03-20 |
2021-10-19 |
Plexxikon Inc. |
Compounds and methods for IDO and TDO modulation, and indications therefor
|
|
SG11202008593PA
(en)
|
2018-03-21 |
2020-10-29 |
Five Prime Therapeutics Inc |
ANTIBODIES BINDING TO VISTA AT ACIDIC pH
|
|
JP7351845B2
(ja)
|
2018-03-23 |
2023-09-27 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
|
|
CA3096674A1
(en)
|
2018-04-12 |
2019-10-17 |
Bristol-Myers Squibb Company |
Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
|
|
CN112292128A
(zh)
|
2018-04-16 |
2021-01-29 |
阿瑞斯医疗有限公司 |
Ep4抑制剂和其用途
|
|
US12037323B2
(en)
|
2018-05-03 |
2024-07-16 |
Bristol-Myers Squibb Company |
Uracil derivatives as Mer-AXL inhibitors
|
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
|
SG11202012973RA
(en)
|
2018-06-27 |
2021-01-28 |
Bristol Myers Squibb Co |
Naphthyridinone compounds useful as t cell activators
|
|
CN112654621B
(zh)
|
2018-06-27 |
2024-05-14 |
百时美施贵宝公司 |
可作为t细胞活化剂的经取代萘啶酮化合物
|
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
|
US12454520B2
(en)
|
2018-07-06 |
2025-10-28 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
MY201995A
(en)
|
2018-07-09 |
2024-03-28 |
Five Prime Therapeutics Inc |
Antibodies binding to ilt4
|
|
AU2019301120A1
(en)
|
2018-07-11 |
2021-02-25 |
Bristol-Myers Squibb Company |
Antibodies binding to VISTA at acidic pH
|
|
EP3823604A4
(en)
|
2018-07-17 |
2022-03-16 |
Board of Regents, The University of Texas System |
COMPOUNDS AS INHIBITORS OF INDOLAMINE-2,3-DIOXYGENASE AND/OR TRYPTOPHANE DIOXYGENASE
|
|
US12059420B2
(en)
|
2018-07-23 |
2024-08-13 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
WO2020023356A1
(en)
|
2018-07-23 |
2020-01-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
US11253525B2
(en)
|
2018-08-29 |
2022-02-22 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
US10959986B2
(en)
|
2018-08-29 |
2021-03-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
EP3846793B1
(en)
|
2018-09-07 |
2024-01-24 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
TWI731420B
(zh)
*
|
2018-09-27 |
2021-06-21 |
大陸商深圳微芯生物科技股份有限公司 |
具有吲哚胺-2,3-雙加氧酶抑制活性的喹啉衍生物及其製備方法、藥物組合物、聯合用藥物與用途
|
|
EP3863722A2
(en)
|
2018-10-10 |
2021-08-18 |
Tilos Theapeutics, Inc. |
Anti-lap antibody variants and uses thereof
|
|
MX2021005708A
(es)
|
2018-11-16 |
2021-09-21 |
Bristol Myers Squibb Co |
Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos.
|
|
AU2019389174A1
(en)
|
2018-11-30 |
2021-07-01 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
GB201820325D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for psma
|
|
GB201820295D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for MT1-MMP
|
|
GB201820288D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicycle Tx Ltd |
Bicycle peptide ligaands specific for MT1-MMP
|
|
EP3897631A4
(en)
|
2018-12-20 |
2022-11-23 |
C4 Therapeutics, Inc. |
TARGETED PROTEIN BREAKDOWN
|
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
|
WO2020128527A1
(en)
|
2018-12-21 |
2020-06-25 |
Bicyclerd Limited |
Bicyclic peptide ligands specific for pd-l1
|
|
EP3897849A1
(en)
|
2018-12-21 |
2021-10-27 |
BicycleTx Limited |
Bicyclic peptide ligands specific for pd-l1
|
|
CA3133155A1
(en)
|
2019-03-19 |
2020-09-24 |
Fundacio Privada Institut D'investigacio Oncologica De Vall Hebron |
Combination therapy for the treatment for cancer
|
|
US20220184222A1
(en)
|
2019-04-02 |
2022-06-16 |
Bicycletx Limited |
Bicycle toxin conjugates and uses thereof
|
|
KR102980990B1
(ko)
|
2019-04-05 |
2026-06-25 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Stat 분해제 및 이의 용도
|
|
WO2020231713A1
(en)
|
2019-05-13 |
2020-11-19 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
|
WO2020231766A1
(en)
|
2019-05-13 |
2020-11-19 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
|
US11458149B1
(en)
|
2019-05-31 |
2022-10-04 |
Ikena Oncology, Inc. |
TEAD inhibitors and uses thereof
|
|
WO2020251972A1
(en)
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
US12624044B2
(en)
|
2019-06-10 |
2026-05-12 |
Kymera Therapeutics, Inc. |
SMARCA degraders and uses thereof
|
|
PH12022500002A1
(en)
|
2019-06-28 |
2023-04-03 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
US20220259212A1
(en)
|
2019-07-11 |
2022-08-18 |
Idorsia Pharmaceuticals Ltd |
Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
|
|
US12558427B2
(en)
|
2019-07-17 |
2026-02-24 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
TWI860386B
(zh)
|
2019-07-30 |
2024-11-01 |
英商拜西可泰克斯有限公司 |
異質雙環肽複合物
|
|
US20220306630A1
(en)
|
2019-08-06 |
2022-09-29 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
|
AR119821A1
(es)
|
2019-08-28 |
2022-01-12 |
Bristol Myers Squibb Co |
Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
|
|
US12215105B2
(en)
|
2019-09-13 |
2025-02-04 |
Nimbus Saturn, Inc. |
HPK1 antagonists and uses thereof
|
|
CA3149719A1
(en)
|
2019-09-19 |
2021-03-25 |
Bristol-Myers Squibb Company |
Antibodies binding to vista at acidic ph
|
|
JP7629459B2
(ja)
|
2019-11-19 |
2025-02-13 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｈｅｌｉｏｓタンパク質の阻害剤として有用な化合物
|
|
AU2020394424A1
(en)
|
2019-11-26 |
2022-06-16 |
Ikena Oncology, Inc. |
Polymorphic carbazole derivatives and uses thereof
|
|
CA3159071A1
(en)
|
2019-11-26 |
2021-06-03 |
Tamar I. ROSENBAUM |
Salts/cocrystals of (r)-n-(4-chlorophenyl)-2-((1s,4s)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide
|
|
WO2021119159A1
(en)
|
2019-12-10 |
2021-06-17 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
CN111333653A
(zh)
*
|
2019-12-16 |
2020-06-26 |
山东大学 |
一种icd诱导剂-ido抑制剂缀合物及制备方法与应用
|
|
CA3161878A1
(en)
|
2019-12-17 |
2021-06-24 |
Matthew M. Weiss |
Irak degraders and uses thereof
|
|
EP4076524A4
(en)
|
2019-12-17 |
2023-11-29 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADERS AND USES THEREOF
|
|
MX2022007369A
(es)
|
2019-12-23 |
2022-07-12 |
Bristol Myers Squibb Co |
Compuestos de quinolinonilo piperazina sustituidos utiles como activadores de celulas t.
|
|
AR120823A1
(es)
|
2019-12-23 |
2022-03-23 |
Bristol Myers Squibb Co |
Compuestos bicíclicos sustituidos útiles como activadores de células t
|
|
JP7677976B2
(ja)
|
2019-12-23 |
2025-05-15 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｔ細胞アクティベーターとして有用な置換ヘテロアリール化合物
|
|
US11679109B2
(en)
|
2019-12-23 |
2023-06-20 |
Kymera Therapeutics, Inc. |
SMARCA degraders and uses thereof
|
|
IL294148A
(en)
|
2019-12-23 |
2022-08-01 |
Bristol Myers Squibb Co |
Substituted quinazolinyl compounds are useful as t-cell activators
|
|
CA3162979A1
(en)
|
2019-12-23 |
2021-07-01 |
Upender Velaparthi |
Substituted piperazine derivatives useful as t cell activators
|
|
BR112022013424A2
(pt)
|
2020-01-06 |
2022-12-13 |
Hifibio Hk Ltd |
Anticorpo anti-tnfr2 e seus usos
|
|
AU2021205143A1
(en)
|
2020-01-07 |
2022-07-28 |
Hifibio, Inc. |
Anti-Galectin-9 antibody and uses thereof
|
|
EP4090663A1
(en)
|
2020-01-15 |
2022-11-23 |
Blueprint Medicines Corporation |
Map4k1 inhibitors
|
|
AR121506A1
(es)
|
2020-03-03 |
2022-06-08 |
Pic Therapeutics Inc |
Inhibidores del eif4e y sus usos
|
|
US20230140384A1
(en)
|
2020-03-09 |
2023-05-04 |
Bristol-Myers Squibb Company |
Antibodies to cd40 with enhanced agonist activity
|
|
WO2021188948A1
(en)
|
2020-03-19 |
2021-09-23 |
Kymera Therapeutics, Inc. |
Mdm2 degraders and uses thereof
|
|
TW202140441A
(zh)
|
2020-03-23 |
2021-11-01 |
美商必治妥美雅史谷比公司 |
經取代之側氧基異吲哚啉化合物
|
|
EP4132971A1
(en)
|
2020-04-09 |
2023-02-15 |
Merck Sharp & Dohme LLC |
Affinity matured anti-lap antibodies and uses thereof
|
|
US20230192867A1
(en)
|
2020-05-15 |
2023-06-22 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
|
EP4161521A4
(en)
|
2020-06-03 |
2024-07-10 |
Kymera Therapeutics, Inc. |
DEUTERED IRAQ DEGRADERS AND USES THEREOF
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
CN111803635B
(zh)
*
|
2020-06-17 |
2023-03-14 |
中国医学科学院基础医学研究所 |
小分子抑制剂在治疗呼吸道病毒性肺炎上的应用
|
|
WO2021258010A1
(en)
|
2020-06-19 |
2021-12-23 |
Gossamer Bio Services, Inc. |
Oxime compounds useful as t cell activators
|
|
US11839659B2
(en)
|
2020-07-02 |
2023-12-12 |
Northwestern University |
Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein
|
|
AU2021316053A1
(en)
|
2020-07-30 |
2023-03-02 |
Kymera Therapeutics, Inc. |
Methods of treating mutant lymphomas
|
|
CN116348476A
(zh)
|
2020-08-03 |
2023-06-27 |
拜斯科技术开发有限公司 |
基于肽的接头
|
|
KR20230077722A
(ko)
|
2020-08-10 |
2023-06-01 |
지브이20 테라퓨틱스 엘엘씨 |
Igsf8을 표적화하여 자가면역 질환 및 암을 치료하기 위한 조성물 및 방법
|
|
WO2022038158A1
(en)
|
2020-08-17 |
2022-02-24 |
Bicycletx Limited |
Bicycle conjugates specific for nectin-4 and uses thereof
|
|
EP4228764A1
(en)
|
2020-10-14 |
2023-08-23 |
Five Prime Therapeutics, Inc. |
Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
|
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
EP4255895A1
(en)
|
2020-12-02 |
2023-10-11 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
US12606568B2
(en)
|
2020-12-09 |
2026-04-21 |
Kymera Therapeutics, Inc. |
SMARCA degraders and uses thereof
|
|
AU2021400725A1
(en)
|
2020-12-16 |
2023-08-03 |
Gossamer Bio Services, Inc. |
Compounds useful as t cell activators
|
|
AR124547A1
(es)
|
2020-12-30 |
2023-04-05 |
Kymera Therapeutics Inc |
Degradadores de irak y sus usos
|
|
US20250186539A2
(en)
|
2021-01-11 |
2025-06-12 |
Bicycletx Limited |
Methods for treating cancer
|
|
JP2024506858A
(ja)
|
2021-02-02 |
2024-02-15 |
リミナル・バイオサイエンシーズ・リミテッド |
Ｇｐｒ８４アンタゴニストおよびその使用
|
|
KR20230153387A
(ko)
|
2021-02-02 |
2023-11-06 |
리미널 바이오사이언시스 리미티드 |
Gpr84 길항제 및 이의 용도
|
|
WO2022169921A1
(en)
|
2021-02-04 |
2022-08-11 |
Bristol-Myers Squibb Company |
Benzofuran compounds as sting agonists
|
|
MX2023009379A
(es)
|
2021-02-12 |
2023-10-10 |
Hoffmann La Roche |
Derivados de tetrahidroazepina biciclicos para el tratamiento del cancer.
|
|
WO2022174253A1
(en)
|
2021-02-12 |
2022-08-18 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
MX2023009178A
(es)
|
2021-02-15 |
2023-08-21 |
Kymera Therapeutics Inc |
Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
|
|
WO2022174268A1
(en)
|
2021-02-15 |
2022-08-18 |
Kymera Therapeutics, Inc. |
Irak4 degraders and uses thereof
|
|
BR112023017582A2
(pt)
|
2021-03-05 |
2023-12-05 |
Univ Basel |
Composições para o tratamento de doenças ou condições associadas ao ebv
|
|
EP4052705A1
(en)
|
2021-03-05 |
2022-09-07 |
Universität Basel Vizerektorat Forschung |
Compositions for the treatment of ebv associated diseases or conditions
|
|
CN117295737A
(zh)
|
2021-03-05 |
2023-12-26 |
林伯士萨顿公司 |
Hpk1拮抗剂和其用途
|
|
JP2024510176A
(ja)
|
2021-03-08 |
2024-03-06 |
ブループリント メディシンズ コーポレイション |
Ｍａｐ４ｋ１阻害剤
|
|
US11918582B2
(en)
|
2021-03-15 |
2024-03-05 |
Rapt Therapeutics, Inc. |
Pyrazole pyrimidine compounds and uses thereof
|
|
WO2022213062A1
(en)
|
2021-03-29 |
2022-10-06 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
JP2024514530A
(ja)
|
2021-04-02 |
2024-04-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
切断型ｃｄｃｐ１に対する抗体およびその使用
|
|
EP4320125A1
(en)
|
2021-04-05 |
2024-02-14 |
Bristol-Myers Squibb Company |
Pyridinyl substituted oxoisoindoline compounds for the treatment of cancer
|
|
PE20231941A1
(es)
|
2021-04-06 |
2023-12-05 |
Bristol Myers Squibb Co |
Compuestos de oxoisoindolina sustituidos con piridinilo
|
|
US12325697B2
(en)
|
2021-04-09 |
2025-06-10 |
Nimbus Clio, Inc. |
CBL-B modulators and uses thereof
|
|
AU2022258968A1
(en)
|
2021-04-16 |
2023-10-19 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
CA3217792A1
(en)
|
2021-05-07 |
2022-11-10 |
Kymera Therapeutics, Inc |
Cdk2 degraders and uses thereof
|
|
MX2024000751A
(es)
|
2021-07-14 |
2024-03-25 |
Blueprint Medicines Corp |
Compuestos heterociclicos como inhibidores de map4k1.
|
|
US20240336630A1
(en)
|
2021-07-15 |
2024-10-10 |
Blueprint Medicines Corporation |
Map4k1 inhibitors
|
|
US12157732B2
(en)
|
2021-08-25 |
2024-12-03 |
PIC Therapeutics, Inc. |
eIF4E inhibitors and uses thereof
|
|
IL310924A
(en)
|
2021-08-25 |
2024-04-01 |
Pic Therapeutics Inc |
Eif4e inhibitors and uses thereof
|
|
JP2024540080A
(ja)
|
2021-10-29 |
2024-10-31 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ４分解剤およびその合成
|
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
WO2023122772A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Oxime derivatives useful as t cell activators
|
|
WO2023122777A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Oxime derivatives useful as t cell activators
|
|
WO2023122778A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Pyridazinone derivatives useful as t cell activators
|
|
EP4472967A4
(en)
|
2022-01-31 |
2026-04-15 |
Kymera Therapeutics Inc |
Iraqi Degradation Agents and Their Uses
|
|
CN118946556A
(zh)
|
2022-02-01 |
2024-11-12 |
阿维纳斯运营公司 |
Dgk靶向化合物及其用途
|
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
|
CN119768393A
(zh)
|
2022-05-25 |
2025-04-04 |
医肯纳肿瘤学公司 |
Mek抑制剂和其用途
|
|
EP4565568A1
(en)
|
2022-08-02 |
2025-06-11 |
Liminal Biosciences Limited |
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
|
|
WO2024028365A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Substituted pyridone gpr84 antagonists and uses thereof
|
|
EP4565569A1
(en)
|
2022-08-02 |
2025-06-11 |
Liminal Biosciences Limited |
Aryl-triazolyl and related gpr84 antagonists and uses thereof
|
|
KR20250046309A
(ko)
|
2022-08-08 |
2025-04-02 |
브리스톨-마이어스 스큅 컴퍼니 |
T 세포 활성화제로서 유용한 치환된 테트라졸릴 화합물
|
|
US20260049076A1
(en)
|
2022-08-09 |
2026-02-19 |
Bristol-Myers Squibb Company |
Tertiary Amine Substituted Bicyclic Compounds Useful as T Cell Activators
|
|
WO2024033457A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
|
WO2024033458A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives
|
|
US20260035364A1
(en)
|
2022-08-11 |
2026-02-05 |
Hoffmann-La Roche Inc. |
Bicyclic tetrahydrothiazepine derivatives
|
|
CN119677733A
(zh)
|
2022-08-11 |
2025-03-21 |
豪夫迈·罗氏有限公司 |
双环四氢硫氮杂䓬衍生物
|
|
WO2024112894A1
(en)
|
2022-11-22 |
2024-05-30 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
CN116143726B
(zh)
*
|
2022-12-02 |
2024-09-06 |
广州市联瑞制药有限公司 |
一种环磷腺苷杂质的制备方法
|
|
WO2024137865A1
(en)
|
2022-12-22 |
2024-06-27 |
Gossamer Bio Services, Inc. |
Compounds useful as t cell activators
|
|
ES3075944T3
(en)
|
2023-05-08 |
2026-08-10 |
Bristol Myers Squibb Co |
Substituted phenyl oxazolone compounds
|
|
CN121666382A
(zh)
|
2023-05-10 |
2026-03-13 |
缆图药品公司 |
GSK3α抑制剂和其使用方法
|
|
CN121368591A
(zh)
|
2023-05-31 |
2026-01-20 |
百时美施贵宝公司 |
用于降低ikzf 1-4蛋白水平的经取代的噁唑酮化合物
|
|
EP4724149A1
(en)
|
2023-06-07 |
2026-04-15 |
Bristol-Myers Squibb Company |
Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound
|
|
KR20260028777A
(ko)
|
2023-06-23 |
2026-03-04 |
브리스톨-마이어스 스큅 컴퍼니 |
항암제로서의 치환된 옥소이소인돌리닐 피페리딘-2,6-디온 화합물
|
|
US20250059164A1
(en)
|
2023-06-23 |
2025-02-20 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2025030002A2
(en)
|
2023-08-02 |
2025-02-06 |
Arvinas Operations, Inc. |
Dgk targeting compounds and uses thereof
|
|
EP4784572A1
(en)
|
2023-09-02 |
2026-08-05 |
Bristol-Myers Squibb Company |
Substituted azetidinyl oxoisoindolinyl piperidine-2,6-dione compounds
|
|
CN121752560A
(zh)
|
2023-09-02 |
2026-03-27 |
百时美施贵宝公司 |
经取代的苯基氧代噁唑基哌啶二酮化合物
|
|
AR133800A1
(es)
|
2023-09-13 |
2025-11-05 |
Bristol Myers Squibb Co |
Compuestos de oxoisoindolinil piperidina-2,6-diona sustituida
|
|
CN122180680A
(zh)
|
2023-10-31 |
2026-06-09 |
百时美施贵宝公司 |
泛素特异性加工蛋白酶1(usp1)化合物
|
|
KR20260109851A
(ko)
|
2023-10-31 |
2026-07-13 |
브리스톨-마이어스 스큅 컴퍼니 |
유비퀴틴 특이적 프로세싱 프로테아제 1 (usp1) 화합물
|
|
WO2025096490A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096487A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096494A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
IL327996A
(en)
|
2023-10-31 |
2026-06-01 |
Bristol Myers Squibb Co |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
CN122422311A
(zh)
|
2023-10-31 |
2026-07-17 |
百时美施贵宝公司 |
泛素特异性加工蛋白酶1 (usp1)化合物
|
|
WO2025226767A1
(en)
|
2024-04-24 |
2025-10-30 |
Bristol-Myers Squibb Company |
Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds for use in the treatment of cancer
|
|
WO2026035787A1
(en)
|
2024-08-07 |
2026-02-12 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) macrocyles
|
|
WO2026080794A1
(en)
|
2024-10-11 |
2026-04-16 |
Bristol-Myers Squibb Company |
Chemical compounds useful for degrading proteins
|
|
WO2026090348A1
(en)
|
2024-10-24 |
2026-04-30 |
Mirati Therapeutics, Inc. |
The use of son of sevenless (sos) inhibitor compounds such as 7-substituted benzofurans to treat cancer
|
|
WO2026112386A1
(en)
|
2024-11-22 |
2026-05-28 |
Bristol-Myers Squibb Company |
Substituted oxoisoindolinyl piperidine-2,6-dione compounds and methods of degrading proteins
|
|
CN119707950A
(zh)
*
|
2024-12-24 |
2025-03-28 |
无锡市南京大学锡山应用生物技术研究所 |
一种用于免疫蛋白靶向降解的嵌合体及其制备方法和应用
|